Pharmacokinetics of Cisplatin and its Metabolites Following Intravenous Administration in Cancer Patients of Bangladesh

  • AKM Shahidur Rahman Associate Professor & HOD, Departmennt of Pharmacology & Therapeutics Khwaja Yunus Ali Medical College, Enayetpur, Sirajgonj
  • Anwar Ul Islam Professor, Department of Pharmacy, University of Rajshahi, Rajshahi
  • Mir Misbahuddin Professor, Departmennt of Pharmacology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka
  • Nishat Parvin Associate Professsor, Dental Unit, Rajshahi Medical College, Rajshahi
Keywords: Bioavailibiity, Cisplatin, Metabolites and Cancer patients

Abstract

Background: To determine the mean bioavailability of cisplatin at different time interval after intravenous administration of cisplatin of 18-60 years old 50 male Bangladeshi cancer patients.

Materials & Methods: Pharmacokinetic and demographic data were collected from 50 various types of male cancer patients received injection cisplatin 50 mg/m2 infusion for over 3 hours every alternate week for 3 weeks and mean population bioavailability were determined.

Results: Statistical analysis from data of HPLC reported that the highest mean plasma concentration of cisplatin was found 428.32 μg/dl (±6.092) after 3 hours and highest mean urinary concentration of cisplatin was found 996.56μg/dl (±1.97) after 12 hours (P<0.05). Highest and lowest concentration of four suspected metabolites (CM2, CM3, CM4 and CM5) were identified in blood and corresponding urine with their specific RT (retention time) and Area (P<0.01) which suggestive of previous work.

Conclusion: Following I/V administration plasma concentration of cisplatin at different time interval determined the proper dosing dosing interval of the drug and reduce toxicity.

KYAMC Journal Vol. 9, No.-3, October 2018, Page 110-114

Downloads

Download data is not yet available.
Abstract
288
PDF
241
Published
2018-12-04
How to Cite
Rahman, A., Islam, A., Misbahuddin, M., & Parvin, N. (2018). Pharmacokinetics of Cisplatin and its Metabolites Following Intravenous Administration in Cancer Patients of Bangladesh. KYAMC Journal, 9(3), 110-114. https://doi.org/10.3329/kyamcj.v9i3.38781
Section
Original Articles